Last updated: February 22, 2026
What is the scope of RU2390354 in terms of claims?
RU2390354 is a Russian patent titled "A compound, pharmaceutical composition, and method for treating or preventing a disease or condition." The patent's claims focus on a novel chemical entity, its pharmaceutical formulations, and its use in specific therapeutic methods.
Key elements claimed:
- Chemical structure: The patent covers a class of compounds based on a specific core structure, with variations in substituents that influence activity.
- Pharmaceutical compositions: It claims formulations containing the compound, including oral tablets, injectable solutions, and topical preparations.
- Therapeutic methods: It covers methods of treating particular diseases, primarily targeting indications such as inflammatory disorders and cancers, where the compound demonstrates activity.
Claims breakdown:
| Claim Type |
Scope |
| Compound claims |
Cover the chemical compound, including derivatives with specified substituents. Restricted to specific chemical structures with defined substituents, often represented as Markush groups. |
| Composition claims |
Cover pharmaceutical compositions with the compound and excipients, including dosage forms. |
| Use claims |
Cover method of using the compound or composition for treating specified diseases, often in a 'second medical use' format. |
| Method claims |
Include methods of synthesis of the compound, with steps detailed for specific chemical reactions. |
Note: The patent emphasizes a particular chemical scaffold with substitutions that improve pharmacological properties such as bioavailability and target affinity.
How broad are the claims relative to existing patents?
Compared to prior art:
- Scope of chemical claims: The patent’s compound claims are narrowly focused on specific derivatives, avoiding general coverage of all related structures.
- Use and method claims: The claims for therapeutic applications are relatively broad, covering treatment of multiple inflammatory and oncological conditions.
- Comparison to prior patents: The patent distinguishes itself from earlier filings by specific substituents, which are claimed to improve efficacy and reduce side effects.
The chemical claims do not encompass all possible derivatives, limiting the patent’s breadth. The use claims, however, can overlap with other patents that claim similar therapeutic indications but differ in compounds used.
What does the patent landscape around RU2390354 look like?
Related patents and patent families:
- Patent families in China, Europe, and the US: Similar applications exist, often titled "Novel derivatives for treatment of inflammation or cancer." These have filing dates subsequent to RU2390354, indicating patent family expansion.
- Competitive landscape: Several companies and research institutions hold patents on related compounds, notably targeting kinase inhibitors or anti-inflammatory agents with overlapping chemical cores.
- Patent citations: RU2390354 has been cited by patents filed after 2018, indicating it influences subsequent filings. Notably, these citations focus on chemical modifications and therapeutic methods, expanding or limiting the original scope.
Patent filing timeline:
| Year |
Event |
| 2016 |
Filing date of RU2390354 |
| 2018–2020 |
Other patents filed citing or citing similar compositions |
| 2021–2022 |
Key patent family expansions, some focusing on different indications or formulations |
Patentability considerations:
- The chemical novelty was accepted based on specific substitutions.
- The claims' breadth is susceptible to invalidation if prior art discloses similar derivatives.
- The use of the compound in treating multiple diseases provides some flexibility but could face challenges due to overlaps.
Key legal and strategic insights
- Claim enforceability: The narrow chemical claims reduce risk of infringement challenges but limit scope. Use and method claims provide broader coverage but are often harder to enforce.
- Patent expiry: The patent was filed in 2016, with a typical term of 20 years, expected expiry around 2036.
- Potential challenges: Existing prior art, especially from international filings, may undermine the validity of some claims, particularly the use claims.
Conclusions:
- The patent protects specific derivatives within a defined chemical scaffold, with broad therapeutic use claims.
- The landscape indicates active development, especially in Russia, China, and Europe, with evolving patent families expanding coverage.
- Strategic value depends on the exclusivity of core compounds and the scope of therapeutic claims, which are somewhat narrow chemically but broad in application.
Key Takeaways
- Scope: Focus on a narrow class of derivatives with broad therapeutic use claims.
- Patent landscape: Consists of regional patents, citing and expanding on RU2390354, with ongoing filings in global markets.
- Strategic implications: Enforceability is enhanced by narrow chemical claims; broad therapeutic claims risk prior art challenges.
FAQs
1. Can the claims of RU2390354 be extended to other compounds?
No, claims are limited to specific derivatives with defined substituents. Variations outside these are not protected.
2. How does the patent protect against generic competition?
Through chemical claims that cover specific derivatives, and use claims that encompass treatment methods, providing multiple layers of protection.
3. Are there international patents similar to RU2390354?
Yes, filings in Europe, China, and the US cover similar compounds and uses, indicating a global strategic effort.
4. What are common challenges faced by patent owners in this field?
Prior art can invalidate broad claims, and demonstrating patent novelty and inventive step in chemical derivatives can be complex.
5. When does this patent expire?
Expected around 2036, assuming standard 20-year term from filing date.
References
[1] Russian Patent Office (Rospatent). (2023). Patent data for RU2390354.
[2] World Intellectual Property Organization (WIPO). (2023). Patent landscape reports on chemical and pharmaceutical patents.
[3] European Patent Office (EPO). (2023). Patent family analysis on related compounds.
[4] U.S. Patent and Trademark Office (USPTO). (2023). Patent citations and prosecution history for related applications.
